Sign inCreate account

Report workspace tools

NCT02584608COMPLETEDanonymous

Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis

Sponsor

Source record

Indiana University

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

ACTIMMUNE

Indication / condition

AI-normalized

Autosomal Dominant Osteopetrosis Type 2

Intervention

Source record

ACTIMMUNE

Source & freshness

Source record

NCT ID

NCT02584608

Original source

ClinicalTrials.gov

Source last updated

Jan 08, 2021

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02584608

Title

Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis

Sponsor

Indiana University

Status

COMPLETED

Phase

PHASE2

Condition raw

Autosomal Dominant Osteopetrosis Type 2

Condition normalized

Autosomal Dominant Osteopetrosis Type 2

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ACTIMMUNE

Target normalized

ACTIMMUNE

Interventions

ACTIMMUNE

Public preview

Source record

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02584608

Status

COMPLETED

Phase

PHASE2

Sponsor

Indiana University

Executive brief

Investment-Ready Snapshot

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 08, 2021
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02584608

Indication

Autosomal Dominant Osteopetrosis Type 2

Modality

small molecule

Target

ACTIMMUNE

Intervention

ACTIMMUNE

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.